LRRK2 and Parkinson disease: Many of the pathogenic LRRK2 mutants display an increase in the kinase activity compared to wild-type (WT) LRRK2 [68,69,70], and genetic or pharmacological inhibition of the kinase activity could alleviate neurodegeneration induced by pathogenic LRRK2 mutants [71], suggesting that aberrant kinase activity plays a key role in the pathogenesis of PD [64,72].